SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study
Yanfang Yang, Yaoyang Guo, Mingyu Zhu, Ziyi Dong, Siqi Jiang, Xinyi Wen, Zhansheng Jiang · 2026
Read SMARCA4 mutations drive metastatic progression and predict poor survival in breast cancer based on a real-world cohort study by Yanfang Yang, Yaoyang Guo, Mingyu Zhu, Ziyi Dong, Siqi Jiang, Xinyi Wen, Zhansheng Jiang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13212835.txt.
Description
Yanfang Yang and co-authors test whether one gene's faults mark out the most dangerous breast cancers in this 2026 study. The gene, SMARCA4, helps run the machinery that opens and closes DNA. Its role in breast cancer spread and survival had not been measured in a large real-world group.
The team drew on records of 4,032 patients and found mutations in about one percent, forty-nine people. Those patients showed far more spread to bone and lymph nodes than patients without the fault. Their survival was shorter, and the usual comfort of hormone-sensitive or HER2-positive status faded in this group. Their tumors carried more mutations overall and often paired the fault with two other cancer genes. The authors name the mutation an independent warning sign, raising death risk by about sixty percent, and propose it as a marker for closer watching.
Catalog record
| CREATOR | Yanfang Yang, Yaoyang Guo, Mingyu Zhu, Ziyi Dong, Siqi Jiang, Xinyi Wen, Zhansheng Jiang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |